Nanobodies targeting ABCC3 for immunotargeted applications in glioblastoma

The cancer “omics” reveal many clinically relevant alterations that are transforming the molecular characterization of glioblastomas. However, many of these findings are not yet translated into clinical practice due, in part, to the lack of non-invasive biomarkers and the limitations imposed by the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz-López, Eduardo, Jovčevska, Ivana, González-Gómez, Ruth, Tejero, Héctor, Al-Shahrour, Fátima, Muyldermans, Serge, Schuhmacher, Alberto J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803684/
https://www.ncbi.nlm.nih.gov/pubmed/36585418
http://dx.doi.org/10.1038/s41598-022-27161-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803684/
https://www.ncbi.nlm.nih.gov/pubmed/36585418
http://dx.doi.org/10.1038/s41598-022-27161-3

Ejemplares similares